Research and Development Program Sample Clauses
Research and Development Program. 18.1 A Research and Development Program shall exist to take advantage of teacher resources for the improvement of the schools by affording personnel opportunities to work on self-initiated proposals. Proposals for projects to be carried out under the Research and Development Program may include such matters as curriculum planning, evaluation and selection of new materials, development of original materials, plans for implementing new teaching techniques, preparation of student reading lists, setting up experimental laboratory blocks, evaluation system, or any other worthwhile endeavor. No person who has submitted an R & D proposal will participate in deliberations on Research and Development Programs for that particular year.
18.2 Any teacher or teachers may submit to the appropriate Administrators, a proposal in which the following are indicated:
a) Describe the nature of the work and what it might accomplish in terms of meeting an identified need.
1. Document the need as well as possible.
2. Develop objectives to meet the need.
b) Describe the procedures that will be used to achieve the objectives including:
1. The number and names of teachers the project would involve with a contact person indicated.
2. The estimated length of time required to complete the project. Proposed dates would be helpful, if possible.
3. A schedule or sequence for accomplishment of the different objectives or phases of the project.
4. An estimate of expenses for supplies, materials, travel, consultants, teachers' salaries (at the rate given in 22.10), and R&D leader’s salary (at the rate given in 22.10) with subtotals and a grand total for the cost of the proposed project.
c) Describe the evaluation procedures to be used.
1. What method of evaluation do you plan for your proposal?
2. What criteria will be used to determine the success or relative success of the proposal?
18.3 Teachers making a proposal for a project under this program must submit their proposal, as described in Section 22.2, to the Central Office no later than April 1. Such proposal must be in writing, but may be in outline form.
18.4 A teacher or teachers who submit such a proposal will receive written notification of the Superintendent's action on it whenever practicable by April 15th, but no later than May 15th. Action by the Superintendent may take any of the following forms.
a) Approval.
Research and Development Program. GENENCOR agrees to apply its Directed Evolution Technology to the R&D Program and to provide DuPont with results obtained from such application showing an improvement over the starting material(s) based on the stated intent of the experiment, such results to include Materials as defined in the Master Biological Material Transfer Agreement, Appendix 9.2 ("Results"). GENENCOR will disclose to DUPONT sufficient information for DUPONT to make use of the Results in the DuPont Field, except that GENENCOR shall have no obligation to disclose to DUPONT information on the underlying experimentation, techniques or analyses leading to the Results to the extent said information would provide DUPONT enabling disclosure of the Directed Evolution Technology.
Research and Development Program. Subject to the terms and conditions set forth herein, Solazyme and Dow shall conduct a research and development program in accordance with the written plan attached as Exhibit A (the “Research and Development Plan”). The Research and Development Plan may be amended by mutual agreement of the Parties. It is contemplated that there will/may be multiple Research and Development Plans that shall be sequentially numbered referencing different projects, and such agreed-upon additional Research and Development Plans shall be attached as part of Exhibit A and Incorporated herein.
Research and Development Program. Utilizing its Best Efforts and with the assistance of THERAPEUTICS, INNOVATIVE will establish an integrated Development Plan for the implementation of research and development programs for all Category III SDC Product(s) evaluated and identified under Section 3.3(a) that, in its exercise of sound business judgment, it deems worth pursuing. The Development Plan, with mutually agreed-upon performance standards and criteria, including time and event scheduling, will identify potential SDC Personal Care candidates under Category III, as set forth in Section 3.0, for development and THERAPEUTICS shall collaborate and assist INNOVATIVE in identifying Category III SDC Product candidates. Upon evaluation, identification and approval by the EMC of such Category III SDC products, INNOVATIVE will conduct or have conducted all product development, as more fully set forth in Section 3.0 hereof and bear full responsibility for all studies associated with the research and development of all Category III SDC Product(s) exclusive of products categorized by the FDA as OTC drug products The product development of the aforementioned OTC products is the responsibility of THERAPEUTICS. W02-W97-oc:LGA\41332973.5 FINAL DEVELOPMENT AND LICENSING AGREEMENT CONFIDENTIAL DATED SEPTEMBER 5, 2003 BY AND BETWEEN INNOVATIVE MEDICAL SERVICES AND THERAPEUTICS, INC. Page 15 OF 43
Research and Development Program. Using the Steering Committee as the device through which agreement is reached, DUPONT and GENENCOR will jointly agree on the research and development work to be performed under the Agreement, including which Party is responsible for such work, whether it is to be performed jointly by the Parties or solely by one of the Parties, relevant time lines for progress of such work and such other factors as are deemed necessary and appropriate to conduct the work. A summary of the work to be performed under the Agreement, including the initial R&D Program proposal (the "R&D Program"), is attached to and incorporated in the Agreement as Appendix 2.2.
Research and Development Program. Based upon its expertise and on a commercially reasonable basis exercising its Best Efforts, THERAPEUTICS will establish an integrated Development Plan for the implementation of research and development programs for each SDC Product(s) evaluated and identified under Section 3.3(a) that, in its exercise of sound business judgment, it deems worth pursuing. The Development Plan, with mutually agreed upon performance standards and criteria, including time and event scheduling, will identify potential SDC Healthcare Product candidates, under Categories I and II, as set forth in Section 3.0, for development by either THERAPEUTICS or a Third Party(s). THERAPEUTICS shall collaborate and assist INNOVATIVE in identifying Category III SDC Product candidates. Upon evaluation and identification and SDC Product Categorization and approval by the EMC, THERAPEUTICS will conduct all product development, as more fully set forth in Section 3.0 hereof and bear full responsibility for all technical, scientific and clinical studies associated with the research and development of all Category I and II SDC Product(s) and those Category III SDC Product(s) categorized by the FDA as OTC drug products (Exhibit B as 3A and 3B). W02-W97-oc:LGA\41332973.5 FINAL DEVELOPMENT AND LICENSING AGREEMENT CONFIDENTIAL DATED SEPTEMBER 5, 2003 BY AND BETWEEN INNOVATIVE MEDICAL SERVICES AND THERAPEUTICS, INC. Page 14 OF 43
Research and Development Program. The "Research and Development Program" shall mean the basic research and development program to be conducted jointly by BAVARIAN NORDIC and EPIMMUNE for the construction, design, selection, evaluation and testing of Program Vaccine(s) for use in the Field. An initial description of the Research and Development Program is provided in Appendix I, which is incorporated herein by reference and made part of this Agreement.
Research and Development Program. (a) Eloxx shall use Commercially Reasonable Efforts to conduct the activities set forth in
(i) SAD Activity Plan and (ii) the Eloxx Transitional Plan, to Develop the Licensed Compound.
(b) Following completion of the Eloxx Transitional Plan, as between Licensee and Eloxx, Licensee shall have responsibility and sole decision-making authority, for progressing the Development and Commercialization of Licensed Products.
Research and Development Program. 4.1 OBJECTIVES OF THE R&D PROGRAM. The objectives of the R&D Program shall be as set forth in Sections 1.15 and 1.43 hereof. In carrying out the R&D Program, AGT and GENOVO shall each use commercially reasonable efforts to perform such tasks as are set forth to be performed by it under the terms of this Agreement, in accordance with all applicable laws, ordinances, rules, regulations, orders, licenses and other requirements now or hereafter in effect.
Research and Development Program. DURACELL and AER shall conduct the Program as set forth in the currently approved version of the Program Objectives. DURACELL shall conduct with AER personnel monthly technology reviews at AER's offices in Smyrna, Georgia or at a mutually acceptable location describing in reasonable detail all Program activities carried out since the date of the last such review (or, in the case of the first such review, since the date hereof) and the results thereof and determining what Program Technology, if any, has been developed since the last such review. After each such review, AER will prepare a written report summarizing such review, subject to approval by DURACELL, which approval shall not be unreasonably withheld.